Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10717326rdf:typepubmed:Citationlld:pubmed
pubmed-article:10717326lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:10717326lifeskim:mentionsumls-concept:C0750572lld:lifeskim
pubmed-article:10717326lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:10717326lifeskim:mentionsumls-concept:C0220812lld:lifeskim
pubmed-article:10717326pubmed:issue2lld:pubmed
pubmed-article:10717326pubmed:dateCreated2000-6-23lld:pubmed
pubmed-article:10717326pubmed:abstractTextAlthough it is commonly assumed that clinical trials are more costly than standard therapy, there have been no previous studies of the cost of conducting phase II trials in lung cancer. We retrospectively analyzed two National Cancer Institute of Canada phase II trials in previously untreated small cell lung cancer (SCLC) to determine the costs of conducting the trials in a cancer treatment centre. Both studies were clinical trials undertaken as part of the NCIC's Investigational New Drug program: IND 69 and IND 50 evaluated docetaxel (taxotere) and gemcitabine, respectively.lld:pubmed
pubmed-article:10717326pubmed:languageenglld:pubmed
pubmed-article:10717326pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10717326pubmed:citationSubsetIMlld:pubmed
pubmed-article:10717326pubmed:statusMEDLINElld:pubmed
pubmed-article:10717326pubmed:monthMaylld:pubmed
pubmed-article:10717326pubmed:issn0169-5002lld:pubmed
pubmed-article:10717326pubmed:authorpubmed-author:HansenDDlld:pubmed
pubmed-article:10717326pubmed:authorpubmed-author:SmithAAlld:pubmed
pubmed-article:10717326pubmed:authorpubmed-author:ListerDDlld:pubmed
pubmed-article:10717326pubmed:authorpubmed-author:PollockDDlld:pubmed
pubmed-article:10717326pubmed:authorpubmed-author:QuinnCClld:pubmed
pubmed-article:10717326pubmed:authorpubmed-author:EvansW KWKlld:pubmed
pubmed-article:10717326pubmed:authorpubmed-author:DahrougeSSlld:pubmed
pubmed-article:10717326pubmed:authorpubmed-author:StapletonJJlld:pubmed
pubmed-article:10717326pubmed:authorpubmed-author:WaterfieldBBlld:pubmed
pubmed-article:10717326pubmed:issnTypePrintlld:pubmed
pubmed-article:10717326pubmed:volume28lld:pubmed
pubmed-article:10717326pubmed:ownerNLMlld:pubmed
pubmed-article:10717326pubmed:authorsCompleteYlld:pubmed
pubmed-article:10717326pubmed:pagination85-95lld:pubmed
pubmed-article:10717326pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:10717326pubmed:meshHeadingpubmed-meshheading:10717326...lld:pubmed
pubmed-article:10717326pubmed:meshHeadingpubmed-meshheading:10717326...lld:pubmed
pubmed-article:10717326pubmed:meshHeadingpubmed-meshheading:10717326...lld:pubmed
pubmed-article:10717326pubmed:meshHeadingpubmed-meshheading:10717326...lld:pubmed
pubmed-article:10717326pubmed:meshHeadingpubmed-meshheading:10717326...lld:pubmed
pubmed-article:10717326pubmed:meshHeadingpubmed-meshheading:10717326...lld:pubmed
pubmed-article:10717326pubmed:meshHeadingpubmed-meshheading:10717326...lld:pubmed
pubmed-article:10717326pubmed:meshHeadingpubmed-meshheading:10717326...lld:pubmed
pubmed-article:10717326pubmed:meshHeadingpubmed-meshheading:10717326...lld:pubmed
pubmed-article:10717326pubmed:year2000lld:pubmed
pubmed-article:10717326pubmed:articleTitleAn estimate of the cost of conducting phase II trials in lung cancer.lld:pubmed
pubmed-article:10717326pubmed:affiliationThe Ottawa Regional Cancer Centre, 190 Melrose Avenue, Ottowa, Canada.lld:pubmed
pubmed-article:10717326pubmed:publicationTypeJournal Articlelld:pubmed